New drug combination for double-expressor lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of targeted drugs and standard chemotherapy for a certain type of lymphoma. It aims to see if the new combination works better than the current standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called double-expressor DLBCL, recently diagnosed.
- You are between 18 and 65 years old.
- You are physically active and able to care for yourself (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan.
- Your heart, liver, kidneys, and blood counts are within normal limits.
- You have not had previous treatment for this lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
This study tests a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) for older adults newly diagnosed with a certain type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this combination is safe and effective for people who may not be able to handle standard, more intense chemotherapy.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
Hear when a new BTK Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.